Back to Trials
NCT07225738RecruitingAccepts Healthy Volunteers

A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

City of Hope Medical Center

Start Date

1/21/2026

Completion Date

8/22/2030

Summary

This study assesses the impact of cannabis (also commonly called marijuana, weed, or THC) use on quality of life among patients with multiple myeloma who are receiving chemotherapy. It also evaluates the potential benefits and harms of cannabis use.

Detailed Description

PRIMARY OBJECTIVES: I. Characterize and compare longitudinal patterns in quality of life, as assessed by the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) instrument, among cannabis users and non-users. II. Estimate and characterize the potential therapeutic benefit and adverse effects associated with cannabis use as assessed by longitudinal patterns of patient reported symptoms (Edmonton Symptoms Assessment Scale-ESAS) and medical assessments (Common Terminology Criteria for Adverse Events-CTCAE v5.0) through a comparative analysis of users and non-users. OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups. GROUP I: Patients complete surveys and undergo blood sample collection throughout the study. GROUP II: Healthcare providers complete a survey on study.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * \* Documented informed consent of the participant * Age: ≥ 18 years * ECOG ≤ 3 * Ability to read and understand English * Patient must be newly diagnosed with a histologically confirmed multiple myeloma * Patients may have started first line therapies and received up to four cycles * HCP SURVEY: Documented informed consent of the participant * HCP SURVEY: Age: ≥ 18 years * HCP SURVEY: Licensed physician, physician assistant, nurse practitioner, or registered nurse * HCP SURVEY: Currently practicing in oncology or providing direct care to oncology patients * HCP SURVEY: Able to read and understand English * HCP SURVEY: Affiliation with City of Hope Exclusion Criteria: * \* Patients may not have completed five cycles of first line therapy or undergone any second line therapy * Other active malignancy * Patients may not have undergone autologous hematopoietic stem cell transplantation * Unable to comply with the study assessments * HCP SURVEY: Reports directly to study PI (Dr. Richard Lee) * HCP SURVEY: Member of the study team or involved in survey design or analysis * HCP SURVEY: Individuals with a real or perceived conflict of interest that could bias survey responses

Interventions

OTHER

Non-Interventional Study

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Multiple Myeloma

Locations

CTCA at Western Regional Medical Center

Goodyear, Arizona 85338

United States

City of Hope Medical Center

Duarte, California 91010

United States

City of Hope Seacliff

Huntington Beach, California 92648

United States

City of Hope at Irvine Lennar

Irvine, California 92618

United States

City of Hope at Long Beach Elm

Long Beach, California 90813

United States

City of Hope at Newport Beach Fashion Island

Newport Beach, California 92660

United States

City of Hope South Pasadena

South Pasadena, California 91030

United States

City of Hope Upland

Upland, California 91786

United States

City of Hope West Covina

West Covina, California 91790

United States

City of Hope Atlanta Cancer Center

Newnan, Georgia 30265

United States

City of Hope at Chicago

Zion, Illinois 60099

United States